Bolt Biotherapeutics (BOLT) just unveiled an update.
Bolt Biotherapeutics, Inc. announced board changes with the resignations of James Healy and Frank D. Lee, effective September 3, 2024; both resignations are amicable without any conflicts. Filling the vacancy, Jakob Dupont, with a robust background in biopharmaceuticals and multiple drug approvals to his credit, joins the board. His term as a Class II member will conclude at the 2026 annual stockholders’ meeting, and he will receive the standard compensation for his role as a non-employee director. Dupont has no undisclosed transactions that could pose conflicts of interest.
Learn more about BOLT stock on TipRanks’ Stock Analysis page.
